These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29098644)

  • 1. Melts of Octaacetyl Sucrose as Oral-Modified Release Dosage Forms for Delivery of Poorly Soluble Compound in Stable Amorphous Form.
    Haznar-Garbacz D; Kaminska E; Zakowiecki D; Lachmann M; Kaminski K; Garbacz G; Dorożyński P; Kulinowski P
    AAPS PharmSciTech; 2018 Feb; 19(2):951-960. PubMed ID: 29098644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Dissolution Medium pH and Simulated Gastrointestinal Contraction on Drug Release From Nifedipine Extended-Release Tablets.
    Gao Z; Ngo C; Ye W; Rodriguez JD; Keire D; Sun D; Wen H; Jiang W
    J Pharm Sci; 2019 Mar; 108(3):1189-1194. PubMed ID: 30343136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine.
    Andreas CJ; Tomaszewska I; Muenster U; van der Mey D; Mueck W; Dressman JB
    Eur J Pharm Biopharm; 2016 Aug; 105():193-202. PubMed ID: 27322002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting the release of nifedipine from a swellable elementary osmotic pump.
    Nokhodchi A; Momin MN; Shokri J; Shahsavari M; Rashidi PA
    Drug Deliv; 2008 Jan; 15(1):43-8. PubMed ID: 18197523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine.
    Ali J; Zgair A; Hameed GS; Garnett MC; Roberts CJ; Burley JC; Gershkovich P
    Int J Pharm; 2019 Jan; 555():228-236. PubMed ID: 30465852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam.
    Van der Vossen AC; Hanff LM; Vulto AG; Fotaki N
    Br J Clin Pharmacol; 2019 Aug; 85(8):1728-1739. PubMed ID: 30964947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.
    Sager M; Schneider F; Jedamzik P; Wiedmann M; Schremmer E; Koziolek M; Weitschies W
    Mol Pharm; 2017 Dec; 14(12):4272-4280. PubMed ID: 29064257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine.
    Gajendran J; Krämer J; Shah VP; Langguth P; Polli J; Mehta M; Groot DW; Cristofoletti R; Abrahamsson B; Dressman JB
    J Pharm Sci; 2015 Oct; 104(10):3289-98. PubMed ID: 26149619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A biorelevant dissolution stress test device - background and experiences.
    Garbacz G; Klein S; Weitschies W
    Expert Opin Drug Deliv; 2010 Nov; 7(11):1251-61. PubMed ID: 20977290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses.
    Garbacz G; Golke B; Wedemeyer RS; Axell M; Söderlind E; Abrahamsson B; Weitschies W
    Eur J Pharm Sci; 2009 Sep; 38(2):147-55. PubMed ID: 19591927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vitro-in vivo correlation study for nifedipine immediate release capsules administered with water, alcoholic and non-alcoholic beverages: Impact of in vitro dissolution media and hydrodynamics.
    Mercuri A; Fares R; Bresciani M; Fotaki N
    Int J Pharm; 2016 Feb; 499(1-2):330-342. PubMed ID: 26721731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and in-vitro evaluation of a modified-release oral dosage form of nifedipine by hybridization of hydroxypropyl-beta-cyclodextrin and hydroxypropylcellulose.
    Wang Z; Horikawa T; Hirayama F; Uekama K
    J Pharm Pharmacol; 1993 Nov; 45(11):942-6. PubMed ID: 7908033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
    Otsuka K; Wagner C; Selen A; Dressman J
    J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sandwiched osmotic tablet core for nifedipine controlled delivery.
    Liu L; Khang G; Rhee JM; Lee HB
    Biomed Mater Eng; 1999; 9(5-6):297-310. PubMed ID: 10822485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of controlled release amorphous solid dispersions (CRASD) using polyvinyl acetate-based release retarding materials: Effect of dosage form design.
    Lugtu-Pe JA; Ghaffari A; Chen K; Kane A; Wu XY
    Eur J Pharm Sci; 2018 Nov; 124():319-327. PubMed ID: 30194980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterising Drug Release from Immediate-Release Formulations of a Poorly Soluble Compound, Basmisanil, Through Absorption Modelling and Dissolution Testing.
    Stillhart C; Parrott NJ; Lindenberg M; Chalus P; Bentley D; Szepes A
    AAPS J; 2017 May; 19(3):827-836. PubMed ID: 28236228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous delivery of Nifedipine and Metoprolol tartarate using sandwiched osmotic pump tablet system.
    Kumaravelrajan R; Narayanan N; Suba V; Bhaskar K
    Int J Pharm; 2010 Oct; 399(1-2):60-70. PubMed ID: 20696225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
    Heigoldt U; Sommer F; Daniels R; Wagner KG
    Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissolution of mesalazine modified release tablets under standard and bio-relevant test conditions.
    Garbacz G; Rappen GM; Koziolek M; Weitschies W
    J Pharm Pharmacol; 2015 Feb; 67(2):199-208. PubMed ID: 25557626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation.
    Wagner C; Thelen K; Willmann S; Selen A; Dressman JB
    J Pharm Sci; 2013 Sep; 102(9):3205-19. PubMed ID: 23696038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.